Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVO-100
- Development stage
- Preclinical
- Lead developer
- AAVivo
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Cell Therapies
01
Overview
AVO-100 is an **AAV-based gene therapy** developed by AAVivo, Inc., designed as an off-the-shelf therapy that generates **CD19-specific chimeric antigen receptor (CAR)-T cells in vivo**. It targets **B-cell malignant neoplasms** by leveraging adeno-associated virus (AAV) vectors to deliver genetic material enabling CAR-T cell production directly within the patient, potentially offering a more accessible alternative to ex vivo CAR-T therapies. Currently in **preclinical development** for immune system and hemic/lymphatic diseases, with highest R&D status as preclinical in the United States as of September 2025.[1][5]
02
Targets
Beyond the preview
Go deeper on AVO-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVO-100.